Latest news with #BarinthusBiotherapeutics
Yahoo
17-07-2025
- Business
- Yahoo
Broadwind Leads The Charge With 2 Other Prominent Penny Stocks
As major U.S. stock indexes hover near all-time highs, investors are navigating a landscape shaped by robust earnings reports and ongoing geopolitical developments. Amidst this backdrop, the concept of penny stocks—though somewhat outdated—remains a relevant investment area for those seeking opportunities in smaller or emerging companies. These stocks can offer potential growth at lower price points, especially when backed by strong financial health and solid fundamentals. In this article, we explore three penny stocks that stand out as promising contenders in the market's current climate. Top 10 Penny Stocks In The United States Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.45 $517.18M ★★★★★★ CuriosityStream (CURI) $4.32 $252.76M ★★★★★★ WM Technology (MAPS) $0.946 $153.53M ★★★★★★ Perfect (PERF) $2.30 $240.36M ★★★★★★ Tuniu (TOUR) $0.9326 $100.42M ★★★★★★ Safe Bulkers (SB) $4.05 $410.26M ★★★★☆☆ Cardno (COLD.F) $0.1701 $6.64M ★★★★★★ BAB (BABB) $0.82788 $5.93M ★★★★★☆ Lifetime Brands (LCUT) $4.45 $102.66M ★★★★★☆ North European Oil Royalty Trust (NRT) $4.76 $44.48M ★★★★★★ Click here to see the full list of 420 stocks from our US Penny Stocks screener. Let's explore several standout options from the results in the screener. Broadwind Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Broadwind, Inc. manufactures and sells structures, equipment, and components for clean technology and other specialized applications in the United States with a market cap of $49.46 million. Operations: Broadwind generates its revenue from three primary segments: Heavy Fabrications at $85.89 million, Gearing at $33.22 million, and Industrial Solutions at $23.71 million. Market Cap: $49.46M Broadwind, Inc. is navigating the penny stock landscape with a market cap of US$49.46 million and diverse revenue streams across Heavy Fabrications, Gearing, and Industrial Solutions totaling over US$140 million annually. Despite being unprofitable currently, it has reduced losses by 19.9% per year over five years and maintains a satisfactory net debt to equity ratio of 18.5%. Recent earnings guidance anticipates annual revenues between US$140 million to US$160 million for 2025. The company has also filed a shelf registration for $1.42 million in common stock offerings related to its ESOP plan, indicating strategic financial maneuvers amidst volatility stabilization at 10%. Dive into the specifics of Broadwind here with our thorough balance sheet health report. Assess Broadwind's future earnings estimates with our detailed growth reports. Barinthus Biotherapeutics Simply Wall St Financial Health Rating: ★★★★★★ Overview: Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company that develops immunotherapeutic drug candidates for auto-immune and inflammatory diseases, with a market cap of $41.15 million. Operations: Barinthus Biotherapeutics plc has not reported any specific revenue segments. Market Cap: $41.15M Barinthus Biotherapeutics, with a market cap of US$41.15 million, operates as a pre-revenue entity in the biotech sector. The company has no debt and holds sufficient cash to cover operations for over three years based on current free cash flow trends. Despite its unprofitability and increasing losses, Barinthus recently presented promising preliminary data from trials involving its VTP-300 drug candidate at the European Association for the Study of the Liver Congress 2025. These trials showed meaningful reductions in hepatitis B surface antigen levels among participants, suggesting potential therapeutic advancements amidst ongoing financial challenges. Click here and access our complete financial health analysis report to understand the dynamics of Barinthus Biotherapeutics. Understand Barinthus Biotherapeutics' earnings outlook by examining our growth report. Baozun Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Baozun Inc. provides end-to-end e-commerce solutions in China and has a market cap of approximately $158.29 million. Operations: The company generates revenue primarily from its E-Commerce segment, which accounts for CN¥8.09 billion, and its Brand Management segment, contributing CN¥1.55 billion. Market Cap: $158.29M Baozun Inc., with a market cap of approximately US$158.29 million, primarily generates revenue from its E-Commerce and Brand Management segments. Despite being unprofitable, the company has reduced its debt significantly over five years and holds more cash than total debt, ensuring a stable financial position. Recent earnings reported CN¥2.06 billion in revenue for Q1 2025 with a net loss of CN¥63.08 million, showing slight improvement from the previous year. Baozun's management team is experienced, and the board is seasoned with an average tenure of 9.7 years, providing strategic stability amid ongoing challenges in profitability growth. Take a closer look at Baozun's potential here in our financial health report. Learn about Baozun's future growth trajectory here. Where To Now? Click through to start exploring the rest of the 417 US Penny Stocks now. Searching for a Fresh Perspective? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BWEN BRNS and BZUN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Business Insider
08-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: US Physical Therapy (USPH) and Barinthus Biotherapeutics (BRNS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on US Physical Therapy (USPH – Research Report) and Barinthus Biotherapeutics (BRNS – Research Report). Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. US Physical Therapy (USPH) In a report released today, Ryan Daniels from William Blair reiterated a Hold rating on US Physical Therapy. The company's shares closed last Wednesday at $70.96. According to Daniels is a 4-star analyst with an average return of 7.7% and a 49.6% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Lifestance Health Group, and Pediatrix Medical Group. The word on The Street in general, suggests a Strong Buy analyst consensus rating for US Physical Therapy with a $108.25 average price target. Barinthus Biotherapeutics (BRNS) In a report released today, Andy Hsieh from William Blair reiterated a Buy rating on Barinthus Biotherapeutics. The company's shares closed last Wednesday at $0.99, close to its 52-week low of $0.80. According to Hsieh is a 4-star analyst with an average return of 6.0% and a 43.7% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Corbus Pharmaceuticals, and Terns Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Barinthus Biotherapeutics with a $4.50 average price target.
Yahoo
26-04-2025
- Business
- Yahoo
Here's Why We're Not Too Worried About Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Barinthus Biotherapeutics (NASDAQ:BRNS) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. Our free stock report includes 3 warning signs investors should be aware of before investing in Barinthus Biotherapeutics. Read for free now. You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. In December 2024, Barinthus Biotherapeutics had US$111m in cash, and was debt-free. In the last year, its cash burn was US$30m. That means it had a cash runway of about 3.7 years as of December 2024. There's no doubt that this is a reassuringly long runway. Depicted below, you can see how its cash holdings have changed over time. View our latest analysis for Barinthus Biotherapeutics In our view, Barinthus Biotherapeutics doesn't yet produce significant amounts of operating revenue, since it reported just US$15m in the last twelve months. As a result, we think it's a bit early to focus on the revenue growth, so we'll limit ourselves to looking at how the cash burn is changing over time. While it hardly paints a picture of imminent growth, the fact that it has reduced its cash burn by 47% over the last year suggests some degree of prudence. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. Even though it has reduced its cash burn recently, shareholders should still consider how easy it would be for Barinthus Biotherapeutics to raise more cash in the future. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn. Since it has a market capitalisation of US$33m, Barinthus Biotherapeutics' US$30m in cash burn equates to about 91% of its market value. Given just how high that expenditure is, relative to the company's market value, we think there's an elevated risk of funding distress, and we would be very nervous about holding the stock. Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Barinthus Biotherapeutics' cash runway was relatively promising. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, we're not too worried about its rate of cash burn. On another note, Barinthus Biotherapeutics has 3 warning signs (and 1 which is significant) we think you should know about. If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
26-04-2025
- Business
- Yahoo
Here's Why We're Not Too Worried About Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Barinthus Biotherapeutics (NASDAQ:BRNS) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. Our free stock report includes 3 warning signs investors should be aware of before investing in Barinthus Biotherapeutics. Read for free now. You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. In December 2024, Barinthus Biotherapeutics had US$111m in cash, and was debt-free. In the last year, its cash burn was US$30m. That means it had a cash runway of about 3.7 years as of December 2024. There's no doubt that this is a reassuringly long runway. Depicted below, you can see how its cash holdings have changed over time. View our latest analysis for Barinthus Biotherapeutics In our view, Barinthus Biotherapeutics doesn't yet produce significant amounts of operating revenue, since it reported just US$15m in the last twelve months. As a result, we think it's a bit early to focus on the revenue growth, so we'll limit ourselves to looking at how the cash burn is changing over time. While it hardly paints a picture of imminent growth, the fact that it has reduced its cash burn by 47% over the last year suggests some degree of prudence. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. Even though it has reduced its cash burn recently, shareholders should still consider how easy it would be for Barinthus Biotherapeutics to raise more cash in the future. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn. Since it has a market capitalisation of US$33m, Barinthus Biotherapeutics' US$30m in cash burn equates to about 91% of its market value. Given just how high that expenditure is, relative to the company's market value, we think there's an elevated risk of funding distress, and we would be very nervous about holding the stock. Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Barinthus Biotherapeutics' cash runway was relatively promising. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, we're not too worried about its rate of cash burn. On another note, Barinthus Biotherapeutics has 3 warning signs (and 1 which is significant) we think you should know about. If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
